HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 372 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR The Barriers to Care Faced by LGBTQ People With Cancer: An... January 21, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Avapritinib July 28, 2020 Opinion: ‘We can’t afford to stop now’ November 30, 2020 Preclinical Study May Have Found New Treatment Option for Triple-Negative Breast... June 8, 2021 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Durvalumab Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... Countdown to 100,000 OncoLife Survivorship Care Plans: What is a Survivorship... Cowboys Fan Battling Metastatic Breast Cancer Gets Surprise From Team’s Quarterback
